INMED PHARMACEUTICALS INC (INM)

CA4576376012 - Common Stock

4.3988  +0.26 (+6.25%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2022 2023 2024
Revenue
YoY % growth
1.09M4.14M
279.82%
4.598M
11.06%
EBITDA
YoY % growth
-13.4M
-36.46%
-8.18M
38.96%
-7.915M
3.24%
EBIT
YoY % growth
-13.59M
-36.72%
-8.38M
38.34%
-8.134M
2.93%
Operating Margin
-1,246.79%-202.42%-176.92%
EPS
YoY % growth
-34.28
9.19%
N/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2022
Q2Q % growth
-14.03
-36.88%
-5.56-8.48-152.57%
Q3 2022
Q2Q % growth
-6.25
39.02%
-6.310.060.99%
Q2 2022
Q2Q % growth
-7.75
24.39%
-5.93-1.82-30.61%
Q1 2022
Q2Q % growth
-6.25
-1,424.39%
-8.842.5929.28%
Q4 2021
Q2Q % growth
-10.25
-2,400.00%
-8.59-1.66-19.39%
Q3 2021
Q2Q % growth
-10.25 -6.06-4.19-69.14%
Q2 2021
Q2Q % growth
-10.25 -6.06-4.19-69.14%
Q1 2021
Q2Q % growth
-0.41 -6.065.6593.23%
Q4 2020
Q2Q % growth
-0.41 -6.065.6593.23%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2025
Q2Q % growth
1.265M
40.52%
%
Q4 2024
Q2Q % growth
1.283M
-44.46%
%
Q3 2024
Q2Q % growth
1.173M
13.84%
%
Q2 2024
Q2Q % growth
1.24M
163.83%
%
Q1 2024
Q2Q % growth
900K
181.25%
%
Q4 2023
Q2Q % growth
2.31M
352.94%
%
Q3 2023
Q2Q % growth
1.03M
232.26%
%
Q2 2023
Q2Q % growth
470K
74.07%
%
Q4 2022
Q2Q % growth
510K 757.5K-247.5K-32.67%
Q3 2022
Q2Q % growth
310K 606K-296K-48.84%
Q2 2022
Q2Q % growth
270K 126.25K143.75K113.86%
Q1 2022
Q2Q % growth
252.5K-252.5K-100.00%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A